nm61591's library 111 articles Export

	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein [My Copy] N Engl J Med, Vol. 359, No. 21. (20 November 2008), pp. 2195-2207. by Paul M. Ridker, Eleanor Danielson, Francisco A. H. Fonseca, et al.Jacques Genest, Antonio M. Gotto, John J. P. Kastelein, Wolfgang Koenig, Peter Libby, Alberto J. Lorenzatti, Jean G. MacFadyen, Borge G. Nordestgaard, James Shepherd, James T. Willerson, Robert J. Glynn, the JUPITER Study Group posted to jupiter inflammation crp by nm61591 on 2009-08-21 15:17:19 as along with 6 people timsenior lula guhjy djmonstermo shoshin fkz1
	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. [My Copy] The New England journal of medicine, Vol. 347, No. 20. (14 November 2002), pp. 1557-1565. by Paul M. Ridker, Nader Rifai, Lynda Rose, Julie E. Buring, Nancy R. Cook posted to crp by nm61591 on 2009-08-21 15:05:58 as
	C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. [My Copy] The New England journal of medicine, Vol. 342, No. 12. (23 March 2000), pp. 836-843. by P. M. Ridker, C. H. Hennekens, J. E. Buring, N. Rifai posted to inflammation cytokines crp biomarkers by nm61591 on 2009-08-21 15:04:02 as
	Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. [My Copy] The New England journal of medicine, Vol. 336, No. 14. (3 April 1997), pp. 973-979. by P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, C. H. Hennekens posted to inflammation cvd by nm61591 on 2009-08-21 15:01:39 as
	Inflammatory markers and risk of developing type 2 diabetes in women. [My Copy] Diabetes, Vol. 53, No. 3. (March 2004), pp. 693-700. by Frank B. Hu, James B. Meigs, Tricia Y. Li, Nader Rifai, JoAnn E. Manson posted to inflammatory cytokines biomarkers by nm61591 on 2009-08-21 14:58:13 as
	C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. [My Copy] Diabetes, Vol. 51, No. 5. (May 2002), pp. 1596-1600. by Dilys J. Freeman, John Norrie, Muriel J. Caslake, et al.Allan Gaw, Ian Ford, Gordon D. Lowe, Denis St S. O'Reilly, Chris J. Packard, Naveed Sattar, West of Scotland Coronary Prevention Study posted to crp by nm61591 on 2009-08-21 14:55:09 as along with 1 person booker
	Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. [My Copy] Diabetes, Vol. 51, No. 4. (April 2002), pp. 1131-1137. by Andreas Festa, Ralph D'Agostino, Russell P. Tracy, Steven M. Haffner, Insulin Resistance Atherosclerosis Study posted to cytokines biomarkers by nm61591 on 2009-08-21 14:53:07 as
	The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. [My Copy] Diabetes, Vol. 50, No. 10. (October 2001), pp. 2384-2389. by J. I. Barzilay, L. Abraham, S. R. Heckbert, et al.M. Cushman, L. H. Kuller, H. E. Resnick, R. P. Tracy posted to inflammation cytokines crp biomarkers by nm61591 on 2009-08-21 14:49:49 as
	C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. [My Copy] JAMA : the journal of the American Medical Association, Vol. 286, No. 3. (18 July 2001), pp. 327-334. by A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, P. M. Ridker posted to il6 cytokines crp by nm61591 on 2009-08-20 17:53:17 as along with 1 person booker
	Inflammation and insulin resistance. [My Copy] The Journal of clinical investigation, Vol. 116, No. 7. (July 2006), pp. 1793-1801. by Steven E. Shoelson, Jongsoon Lee, Allison B. Goldfine posted to insulinresistance inflammation by nm61591 on 2009-08-20 14:56:01 as along with 3 people guhjy amromeo booker
	Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. [My Copy] Journal of molecular medicine (Berlin, Germany), Vol. 81, No. 8. (August 2003), pp. 455-470. by Marc Y. Donath, Joachim Størling, Kathrin Maedler, Thomas Mandrup-Poulsen posted to inflammatory cytokines betacell by nm61591 on 2009-08-20 14:54:24 as
	Is type II diabetes mellitus a disease of the innate immune system? [My Copy] Diabetologia, Vol. 41, No. 10. (October 1998), pp. 1241-1248. by J. C. Pickup, M. A. Crook posted to proinflammatory insulinresistance cytokines biomarkers betacell by nm61591 on 2009-08-20 14:46:50 as
	Inflammation as a cardiovascular risk factor. [My Copy] Circulation, Vol. 109, No. 21 Suppl 1. (1 June 2004) by James T. Willerson, Paul M. Ridker posted to riskfactor review inflammation cytokines cvd crp by nm61591 on 2009-08-20 14:37:53 as
	Insulin as an anti-inflammatory and antiatherogenic modulator. [My Copy] Journal of the American College of Cardiology, Vol. 53, No. 5 Suppl. (3 February 2009) by Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty posted to review insulin inflammatory inflammation cytokines crp by nm61591 on 2009-08-20 14:34:55 as
	Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. [My Copy] The American journal of cardiology, Vol. 99, No. 4A. (19 February 2007) by Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty posted to review insulin inflammatory cytokines crp by nm61591 on 2009-08-20 14:32:37 as
	Correlation between cardiovascular disease and diabetes mellitus: current concepts. [My Copy] The American journal of medicine, Vol. 116 Suppl 5A (8 March 2004) by Richard W. Nesto posted to inflammation crp by nm61591 on 2009-08-20 14:29:13 as
	Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes. [My Copy] Diabetes/metabolism research and reviews, Vol. 25, No. 5. (July 2009), pp. 435-441. by Xiao-Ming M. Mao, Hao Liu, Xiao-Jun J. Tao, Guo-Ping P. Yin, Qian Li, Shu-Kui K. Wang posted to crp by nm61591 on 2009-08-20 14:17:13 as
	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. [My Copy] The New England journal of medicine, Vol. 358, No. 24. (12 June 2008), pp. 2560-2572. by ADVANCE Collaborative Group, Anushka Patel, Stephen MacMahon, et al.John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee, Pavel Hamet, Stephen Harrap, Simon Heller, Lisheng Liu, Giuseppe Mancia, Carl Erik E. Mogensen, Changyu Pan, Neil Poulter, Anthony Rodgers, Bryan Williams, Severine Bompoint, Bastiaan E. de Galan, Rohina Joshi, Florence Travert posted to advance by nm61591 on 2009-04-20 21:09:20 as along with 6 people eplingj timsenior guhjy booker djmonstermo omalbam
	Effects of intensive glucose lowering in type 2 diabetes. [My Copy] The New England journal of medicine, Vol. 358, No. 24. (12 June 2008), pp. 2545-2559. by Action to Control Cardiovascular Risk in Diabetes Study Group, Hertzel C. Gerstein, Michael E. Miller, et al.Robert P. Byington, David C. Goff, J. Thomas Bigger, John B. Buse, William C. Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H. Grimm, Jeffrey L. Probstfield, Denise G. Simons-Morton, William T. Friedewald posted to accord by nm61591 on 2009-04-20 21:03:23 as along with 7 people eplingj thenix booker timsenior guhjy omalbam djmonstermo
	10-year follow-up of intensive glucose control in type 2 diabetes. [My Copy] The New England journal of medicine, Vol. 359, No. 15. (9 October 2008), pp. 1577-1589. by Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, David R. Matthews, H. Andrew Neil posted to ukpds80bg by nm61591 on 2009-04-17 15:09:30 as along with 4 people ggrassi janpalmen guhjy omalbam
	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes [My Copy] N Engl J Med, Vol. 359, No. 15. (9 October 2008), pp. 1565-1576. by Rury R. Holman, Sanjoy K. Paul, Angelyn M. Bethel, Neil, David R. Matthews posted to ukpds80bp by nm61591 on 2009-04-17 15:07:33 as along with 1 person guhjy
	Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. [My Copy] N Engl J Med, Vol. 353, No. 25. (22 December 2005), pp. 2643-2653. by D. M. Nathan, P. A. Cleary, J. Y. Backlund, et al.S. M. Genuth, J. M. Lachin, T. J. Orchard, P. Raskin, B. Zinman, posted to dcctedic by nm61591 on 2009-04-17 14:40:21 as along with 1 person wilvc
	The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. [My Copy] The New England journal of medicine, Vol. 329, No. 14. (30 September 1993), pp. 977-986. posted to dcct by nm61591 on 2009-04-17 14:23:33 as along with 6 people and 2 groups ggrassi waffle168 wilvc mghim worx11 djmonstermo mgh-lcs XROWXR
	The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. [My Copy] Archives of internal medicine, Vol. 157, No. 21. (24 November 1997), pp. 2413-2446. posted to jncvi by nm61591 on 2009-04-16 22:19:26 as
	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. [My Copy] BMJ (Clinical research ed.), Vol. 321, No. 7258. (12 August 2000), pp. 412-419. by A. I. Adler, I. M. Stratton, H. A. Neil, et al.J. S. Yudkin, D. R. Matthews, C. A. Cull, A. D. Wright, R. C. Turner, R. R. Holman posted to ukpds36 by nm61591 on 2009-04-16 22:01:21 as
	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. [My Copy] Journal of the American College of Cardiology, Vol. 53, No. 3. (20 January 2009), pp. 298-304. by Jay S. Skyler, Richard Bergenstal, Robert O. Bonow, et al.John Buse, Prakash Deedwania, Edwin A. Gale, Barbara V. Howard, M. Sue Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S. Sherwin, American Diabetes Association, American College of Cardiology Foundation, American Heart Association posted to accord advance vadt by nm61591 on 2009-01-26 17:48:02 as along with 3 people ggrassi booker guhjy
	Glucose control and vascular complications in veterans with type 2 diabetes. [My Copy] The New England journal of medicine, Vol. 360, No. 2. (8 January 2009), pp. 129-139. by William Duckworth, Carlos Abraira, Thomas Moritz, et al.Domenic Reda, Nicholas Emanuele, Peter D. Reaven, Franklin J. Zieve, Jennifer Marks, Stephen N. Davis, Rodney Hayward, Stuart R. Warren, Steven Goldman, Madeline McCarren, Mary Ellen E. Vitek, William G. Henderson, Grant D. Huang, VADT Investigators posted to accord advance interventionaltrial mortality vadft by nm61591 on 2008-12-24 16:50:25 as along with 7 people and 1 group booker familydoc guhjy omalbam hmoffet richardh djmonstermo Anesthesia and Acute Pain
	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. [My Copy] Circulation (17 December 2008) by Jay S S. Skyler, Richard Bergenstal, Robert O O. Bonow, et al.John Buse, Prakash Deedwania, Edwin A M A. Gale, Barbara V V. Howard, M Sue S. Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S S. Sherwin posted to accord advance interventionaltrial vadft by nm61591 on 2008-12-24 15:57:22 as along with 1 person booker
	Evaluation of Diabetes Management in a Rural Community Hospital [My Copy] Endocrine Practice, Vol. 14, No. 1. (1 January 2008), pp. 50-55. by Ryan Mills, Frank Schwartz, Jay Shubrook posted to file-import-08-12-24 by nm61591 on 2008-12-24 14:29:05 as
	Economic costs of diabetes in the US in 2002. [My Copy] Diabetes Care, Vol. 26, No. 3. (March 2003), pp. 917-932. by P. Hogan, T. Dall, P. Nikolov, posted to cost by nm61591 on 2008-12-23 15:08:56 as along with 2 people mjernigan mmolina
	Intensive Glycemic Control in the ACCORD and ADVANCE Trials. [My Copy] The New England journal of medicine (6 June 2008) by Robert G G. Dluhy, Graham T T. McMahon posted to accord review by nm61591 on 2008-12-14 20:24:44 as along with 4 people stempvoort timsenior guhjy booker
	Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. [My Copy] Lancet, Vol. 366, No. 9500. (26 November 2005), pp. 1849-1861. by A. Keech, R. J. Simes, P. Barter, et al.J. Best, R. Scott, M. R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y. A. Kesäniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso, FIELD study investigators posted to fenofibrate field by nm61591 on 2008-11-17 01:54:46 as along with 1 person guhjy
	Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. [My Copy] Circulation, Vol. 102, No. 1. (4 July 2000), pp. 21-27. posted to fibrate israeli by nm61591 on 2008-11-17 01:52:18 as
	Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. [My Copy] The New England journal of medicine, Vol. 341, No. 6. (5 August 1999), pp. 410-418. by H. B. Rubins, S. J. Robins, D. Collins, et al.C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, T. J. Wilt, J. Wittes posted to gemfibrozil by nm61591 on 2008-11-17 01:49:47 as
	Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. [My Copy] Lancet, Vol. 357, No. 9260. (24 March 2001), pp. 905-910. posted to dais fenofibrate by nm61591 on 2008-11-17 01:46:53 as
	Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. [My Copy] The New England journal of medicine, Vol. 317, No. 20. (12 November 1987), pp. 1237-1245. by M. H. Frick, O. Elo, K. Haapa, et al.O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen posted to gemfibrozil helsinkiheart by nm61591 on 2008-11-17 01:44:05 as
	Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. [My Copy] Archives of internal medicine, Vol. 159, No. 22. (7 1999), pp. 2661-2667. by S. M. Haffner, C. M. Alexander, T. J. Cook, et al.S. J. Boccuzzi, T. A. Musliner, T. R. Pedersen, J. Kjekshus, K. Pyörälä posted to lipids by nm61591 on 2008-11-17 01:41:36 as
	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. [My Copy] Lancet, Vol. 360, No. 9326. (6 July 2002), pp. 7-22. by Heart Protection Study Collaborative Group posted to lipids simvastatin by nm61591 on 2008-11-17 01:33:39 as along with 4 people Penquin007 aleeva journal06 mghim
	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. [My Copy] Lancet, Vol. 366, No. 9493. (8 October 2005), pp. 1267-1278. by C. Baigent, A. Keech, P. M. Kearney, et al.L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes, Cholesterol Treatment Trialists' (CTT) Collaborators posted to lipids meta by nm61591 on 2008-11-17 01:29:30 as along with 1 person ggrassi
	Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. [My Copy] Annals of internal medicine, Vol. 140, No. 8. (20 April 2004), pp. 650-658. by S. Vijan, R. A. Hayward, posted to lipids by nm61591 on 2008-11-17 01:26:41 as
	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. [My Copy] Lancet, Vol. 364, No. 9435. (7 2004), pp. 685-696. by H. M. Colhoun, D. J. Betteridge, P. N. Durrington, et al.G. A. Hitman, H. A. Neil, S. J. Livingstone, M. J. Thomason, M. I. Mackness, V. Charlton-Menys, J. H. Fuller, posted to atorvastatin lipids by nm61591 on 2008-11-17 01:23:48 as
	Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). [My Copy] Diabetes care, Vol. 28, No. 5. (May 2005), pp. 1151-1157. by P. S. Sever, N. R. Poulter, B. Dahlöf, et al.H. Wedel, R. Collins, G. Beevers, M. Caulfield, S. E. Kjeldsen, A. Kristinsson, G. T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren posted to atorvastatin lipids by nm61591 on 2008-11-17 01:20:51 as
	Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. [My Copy] JAMA : the journal of the American Medical Association, Vol. 279, No. 20. (27 May 1998), pp. 1615-1622. by J. R. Downs, M. Clearfield, S. Weis, et al.E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer, A. M. Gotto posted to lipids lovastatin by nm61591 on 2008-11-17 01:18:13 as
	Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). [My Copy] Circulation, Vol. 97, No. 15. (21 April 1998), pp. 1440-1445. posted to lipids pravastatin by nm61591 on 2008-11-17 01:16:09 as
	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. [My Copy] Lancet, Vol. 360, No. 9346. (23 November 2002), pp. 1623-1630. by J. Shepherd, G. J. Blauw, M. B. Murphy, et al.E. L. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, J. W. Jukema, A. M. Kamper, P. W. Macfarlane, A. E. Meinders, J. Norrie, C. J. Packard, I. J. Perry, D. J. Stott, B. J. Sweeney, C. Twomey, R. G. Westendorp, posted to lipids pravastatin by nm61591 on 2008-11-17 01:14:13 as
	Intensive lipid lowering with atorvastatin in patients with stable coronary disease. [My Copy] N Engl J Med, Vol. 352, No. 14. (7 April 2005), pp. 1425-1435. by J. C. LaRosa, S. M. Grundy, D. D. Waters, et al.C. Shear, P. Barter, J. C. Fruchart, A. M. Gotto, H. Greten, J. J. Kastelein, J. Shepherd, N. K. Wenger, posted to atorvastatin lipids by nm61591 on 2008-11-17 01:09:41 as along with 1 person R-MINI
	Intensive versus moderate lipid lowering with statins after acute coronary syndromes. [My Copy] The New England journal of medicine, Vol. 350, No. 15. (8 April 2004), pp. 1495-1504. by Christopher P. Cannon, Eugene Braunwald, Carolyn H. McCabe, et al.Daniel J. Rader, Jean L. Rouleau, Rene Belder, Steven V. Joyal, Karen A. Hill, Marc A. Pfeffer, Allan M. Skene, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators posted to atorvastatin lipids pravastatin by nm61591 on 2008-11-17 01:02:10 as along with 2 people ggrassi djmonstermo
	Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. [My Copy] JAMA : the journal of the American Medical Association, Vol. 287, No. 24. (26 June 2002), pp. 3215-3222. by P. W. Serruys, P. de Feyter, C. Macaya, et al.N. Kokott, J. Puel, M. Vrolix, A. Branzi, M. C. Bertolami, G. Jackson, B. Strauss, B. Meier, posted to fluvastatin lipids by nm61591 on 2008-11-17 00:54:43 as
	Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. [My Copy] Diabetes, Vol. 48, No. 6. (June 1999), pp. 1289-1294. by B. J. Hoogwerf, A. Waness, M. Cressman, et al.J. Canner, L. Campeau, M. Domanski, N. Geller, A. Herd, A. Hickey, D. B. Hunninghake, G. L. Knatterud, C. White posted to lipids prospective by nm61591 on 2008-11-17 00:52:15 as
	Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. [My Copy] The New England journal of medicine, Vol. 339, No. 19. (5 November 1998), pp. 1349-1357. posted to lipids by nm61591 on 2008-11-17 00:50:12 as

Note: You may cite this page as: http://www.citeulike.org/user/nm61591/author/

Result page: 1 2 3 Next

lipids	20
cvd	18
prospective	16
interventionaltrial	13
riskfactor	11
crp	11
review	10
accord	10
cytokines	10
epidemiologic	9
inflammation	8
independentriskfactor	7
biomarkers	5
inflammatory	4
advance	4
atorvastatin	4
pravastatin	4
intensivevsconventional	3
israeli	3
microalbumin	3
vadft	3
meta	3
fenofibrate	2
a1c	2
betacell	2
survival	2
gemfibrozil	2
mortality	2
insulin	2
whitehallstudy	2
simvastatin	2
digami	2
insulinresistance	2
ukpds80bp	1
lovastatin	1
hope	1
il6	1
sprint	1
ukpds36	1
hypoglycemia	1
jupiter	1
lrc-cppt	1
retinopathy	1
fibrate	1
dyslipidemia	1
postprandial	1
kumamoto	1
retrospective	1
dcct	1
steno2	1
vadt	1
ukpds33	1
field	1
ukpds	1
cholestyramine	1
helsinkiheart	1
dais	1
jncvi	1
proinflammatory	1
frammingham	1
fluvastatin	1
followup	1
4s	1
digami2	1
cost	1
ncepatpiii	1
ranchob	1
file-import-08-12-24	1
microvascular	1
ugdp	1
helsinkipol	1
gusto1	1
ukpds35	1
dcctedic	1
oasis	1
ukpds80bg	1
paris	1

nm61591's library 111 articles Export

nm61591's tags